Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Should Breast Cancer Patients Stop Taking Tamoxifen During COVID-19?

Should Breast Cancer Patients Stop Taking Tamoxifen During COVID-19?

The COVID-19 pandemic threatens human health in many ways. Vaccines that have completed phase 3 trials are now in use, but infection risk is expected to continue for some time. During this period, many people will continue to experience severe COVID-19, and some of these patients will unfortunately die. The most common known cause of death in COVID-19 infection is acute respiratory distress syndrome (ARDS). Advanced age, obesity, and chronic diseases such as diabetes mellitus and hypertension are known to increase COVID-19 mortality. There is also evidence that COVID-19 infection causes more deaths in cancer patients.

Increased Thrombosis Risk With Certain Viral Infections

During the H1N1 (2009 swine flu) pandemic, we experienced an increased risk of venous thromboembolism (VTE = clots in the veins) with viral infections (5.9%). However, VTE was found much more frequently in COVID-19 infection than in H1N1 (15-45%). Although the precise mechanism by which COVID-19 increases VTE risk is not known, increased systemic inflammation and endothelial damage are thought to play important roles.

VTE risk increases not only in hospitalized patients but also in outpatient COVID-19 cases. A meta-analysis showed that mortality risk among COVID-19 patients was significantly higher in those with VTE than in those without it (1.74 times). Unless contraindicated, several groups recommend low-molecular-weight heparin (DMAH, a blood thinner) for every COVID patient, but there is no clear consensus.

Endocrine (hormone-suppressing) therapy for hormone-positive breast cancer is the adjuvant (protective) treatment cornerstone. As a selective estrogen receptor modulator (SERM), tamoxifen is used as adjuvant endocrine therapy in many centers worldwide, especially for premenopausal breast cancer patients. Venous thromboembolism is one of Tamoxifen's important side effects.

By What Mechanism Does Tamoxifen Increase Clotting Risk?

Tamoxifen triggering clotting indicates an interaction between estrogen-induced platelet activation and activation due to tamoxifen's cytotoxic (cell-killing) nature. The exact mechanism by which Tamoxifen increases clotting remains to be discovered. However, the abundance of estrogen receptor alpha (ERa) on the surface of platelets, the cells responsible for clotting, may raise VTE risk, the studies suggest.

Although VTE occurs in 4-5% of tamoxifen users, these rates have been shown to increase significantly with tamoxifen use longer than 5 years. VTE risk rises in those with additional risk factors such as obesity, thrombophilia (increased thrombosis risk), smoking and major surgery. There are recommendations to interrupt tamoxifen treatment for 2-3 weeks in patients scheduled for major surgery.

COVID 19 Infection and Tamoxifen Are Independent Risk Factors for VTE

Does COVID-19 infection increase VTE risk in a patient taking tamoxifen, or vice versa? Research tells us that combining independent VTE risk factors increases VTE risk much more. This suggests that the combination of COVID-19 infection and tamoxifen may increase VTE risk.

So what should we do if a breast cancer patient taking adjuvant tamoxifen develops COVID-19 infection?

  • Should We Stop Tamoxifen?
  • If tamoxifen is to be stopped, should we discontinue it for 2-3 weeks, as recommended around surgery?
  • Or should we continue tamoxifen with an anticoagulant (blood thinner)?

In a cancer case report, hyperacute multiorgan thromboembolism was observed in a patient with COVID 19 taking tamoxifen despite anticoagulant therapy. Stopping tamoxifen for at least 2 weeks or longer (because tamoxifen accumulates in fat tissue over the long term) may prevent serious clotting consequences. The Groupe d'intérêt en Hémostase Périopératoire (GIHP) and Groupe Français d'études sur l'Hémostase et la Thrombose (GFHT) recommend stopping tamoxifen treatment to prevent thrombosis in hospitalized COVID-19 patients and patients requiring thromboprophylaxis. In our opinion, stopping tamoxifen treatment in outpatients will also be important in preventing thrombosis. However, breast cancer patients without COVID-19 do not need to stop tamoxifen out of fear of developing COVID-19.

A Surprising Finding That Needs Investigation

Despite this information, some researchers think tamoxifen may be beneficial in COVID-19 patients. In 2013, the FDA approved the use of selective estrogen receptor modulators (SERMs) in ebolavirus infection. Studies were conducted with the idea that SERMs might have similar effects on different viruses. They showed that toremifene (another SERM) may have antiviral effects against MERS-CoV and SARS-CoV, members of the coronavirus family. However, the mechanism by which it acquires antiviral properties is unknown. Although this raises the question of whether SERMs could be used against COVID-19, there are no studies on the subject.

Conclusion

In conclusion, both COVID-19 infection and tamoxifen use are independent VTE risk factors. A 2-3-week interruption of tamoxifen should therefore be considered in a patient taking tamoxifen who develops COVID-19 infection. Similarly, tamoxifen should be interrupted if a breast cancer patient taking it will undergo major surgery. However, breast cancer patients without COVID-19 do not need to stop tamoxifen out of fear of developing COVID-19.

RELATED TOPICS

Sources

Cengiz Karacin, Pinar Karacin & Yakup Ergun. Tamoxifen in breast cancer survivors with COVID 19: stop or go? Medical Oncology volume 2021

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Should Breast Cancer Patients Stop Taking Tamoxifen During COVID-19?

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy